Life at the Johns Hopkins School of Medicine
Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the science behind their drug development program.
One of the hottest topics debated in the 2020 presidential race so far has been immigration reform. There has been widespread outrage centered on the separation of families and the horrible conditions and long stays in detention centers along our southern borders. Detainees hope they’ll be released as soon as possible, but for the children […]
In an essay I published last year for the Lasker Essay Contest (and republished in our blog), I described optogenetics and chemogenetics, two technologies recently developed for basic neuroscience research that have the potential to improve the way we treat psychiatric illness. The major drawback to drugs currently prescribed for diseases such as depression, PTSD, […]
From the flower on your front porch to your cousin’s lower back tattoo, butterflies are one of the most immediately recognizable insects due to their magnificent wings. Though I am no butterfly expert myself, I can distinguish a few species native to my area by their color patterns. Interestingly, wing patterns and coloration may be […]
The technology behind genome sequencing and the science of genomics has advanced incredibly quickly over the past decade. However, in the process, it has come to light that only 1 to 20 percent of common disease heritability can be attributed to the normal genetic sequences of our chromosomes. Instead, epigenetics — in the form of […]